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3Seton Hall University School of Health and Medical Sciences, St Francis Medical Center, Trenton, New Jersey, USAIntroduction: In predialysis chronic kidney disease (CKD), the association of muscle mass with mortality is
poorly deﬁned, and no study has examined outcomes related to the co-occurrence of low muscle mass
and excess adiposity (sarcopenic obesity).
Methods: We examined abnormalities of muscle and fat mass in adult participants of the National Health
and Nutrition Examination Survey 1999–2004. We determined whether associations of body composition
with all-cause mortality differed between participants with CKD compared to those without.
Results: CKD modiﬁed the association of body composition with mortality (P ¼ 0.01 for interaction). In
participants without CKD, both sarcopenia and sarcopenic obesity were independently associated with
increased mortality compared with normal body composition (hazard ratio [HR] ¼ 1.44, 95% conﬁdence
interval [CI] ¼ 1.07–1.93, and HR ¼ 1.64, 95% CI ¼ 1.26–2.13, respectively). These associations were not
present among participants with CKD. Conversely, obese persons had the lowest adjusted risk of death,
with an increased risk among those with sarcopenia (HR ¼ 1.43, 95% CI ¼ 1.05–1.95) but not sarcopenic-
obesity (P ¼ 0.003 for interaction by CKD status; HR ¼ 1.21, 95% CI ¼ 0.89–1.65), compared with obesity.
Discussion: Sarcopenia associates with increased mortality regardless of estimated glomerular ﬁltration
rate, but excess adiposity modiﬁes this association among persons with CKD. Future studies of prognosis
and weight loss and exercise interventions in CKD patients should consider muscle mass and adiposity
together rather than in isolation.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).M uscle wasting is common among patients withend-stage renal disease (ESRD) who are receiving
dialysis, and associates with increased morbidity and
mortality.1–3 In the earlier stages of chronic kidney dis-
ease (CKD), the association of muscle mass with out-
comes is less well deﬁned. There are few data on
mortality associated with sarcopenia, or low muscle
mass, although it is common among individuals with
advanced predialysis kidney disease.4 Studies that
have examined urinary creatinine excretion and total
lean body mass have yielded inconsistent results.5–7
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International Reports (2016) -, -–-Body mass index (BMI) levels in the overweight and
obese range are associated with the lowest mortality
risk in CKD patients.8 However, persons with CKD who
have excess adiposity but are also sarcopenic—a not
uncommon ﬁnding—are very unlikely to be classiﬁed
as obese by BMI.9,10 In hemodialysis patients, this
phenotype, called sarcopenic obesity, is associated with
greater inﬂammation and increased mortality.11 The
prognostic signiﬁcance of sarcopenic obesity in persons
with CKD is not known.12
We hypothesized that sarcopenia and sarcopenic-
obesity are associated with increased all-cause mortality
among individuals with CKD who are not on dialysis. Our
deﬁnition of CKD was restricted to persons with estimated
glomerular ﬁltration rate (eGFR) of <60 ml/min/1.73 m2
because the pathophysiologic link between CKD and
low muscle mass is greatest in this subgroup, and our
prior work demonstrated that the prevalence of sarco-
penia increased below this threshold.10 We tested this1
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National Health and Nutrition Examination Survey
(NHANES), including dual-energy x-ray absorptiometry
(DEXA)derived muscle and fat mass to classify par-
ticipants into 4 mutually exclusive body composition
categories: nonsarcopenic nonobese, obese, sarco-
penic, and sarcopenic-obese.10 Our objective was to
examine this question among persons with CKD and to
determine whether associations differed from those in
individuals without CKD in the same nationally
representative dataset. We hypothesized that associ-
ations of both sarcopenia and sarcopenic obesity with
death would be stronger in persons with CKD than in
those without, as CKD-induced muscle wasting is
likely a poor prognostic factor.
When we initially conducted our analyses, linked
mortality data were available with follow-up through
December 31, 2006. Subsequently, we repeated our
analyses when updated data became available with
mortality status ascertained through December 31,
2011. We considered our ﬁndings from analyses con-
ducted using the 2011 dataset to be our primary
results, given the greater statistical power and longer
follow-up time. However, we also compared the results
obtained using each of these datasets to examine the
impact of the duration of follow-up time on our
ﬁndings.
MATERIALS AND METHODS
Study Population
NHANES 1999–2004 was a program of studies designed
to assess the health and nutritional status of noninsti-
tutionalized civilians in the United States.13 The
NHANES protocol was approved by the National
Center for Health Statistics ethics review board, and
written informed consent was obtained from all par-
ticipants. We examined adults $20 years old (n ¼
15,332) with available body composition data (n ¼
12,732), excluding participants with eGFR <15 ml/min/
1.73 m2 (n ¼ 34) or missing data on covariates of
interest (n ¼ 1082). The resultant cohort had 11,616
participants.
Data Collection
Information on race/ethnicity, education, smoking
status, and comorbidities was based on self-report.
Activity level was calculated as metabolic equivalents
(MET-min/wk) based on questions regarding the fre-
quency and duration of activities such as walking,
cycling, home or yard work, and moderate or vigorous
leisure activity performed within the past 30 days.14
Participants with diabetes mellitus were deﬁned
as those who had a physician diagnosis while not
pregnant, were using insulin or oral hypoglycemic2medications, or had a glycohemoglobin level of
$6.5%. Hypertension was deﬁned by systolic blood
pressure of $140 mm Hg, diastolic blood pressure
of $90 mm Hg, history of physician diagnosis, and/or
antihypertensive medication use.15 Cardiovascular
disease was deﬁned by self-report of a physician
diagnosis of congestive heart failure, coronary heart
disease, angina, myocardial infarction, or stroke.
Serum chemistries were measured using the Hitachi
917 multichannel analyzer (Roche Diagnostics, Indian-
apolis, IN) in 1999 to 2001 and the Beckman Synchron
LX20 (Beckman Coulter Inc., Brea, CA) in 2002 to
2004. C-reactive protein (CRP) was quantiﬁed by latex-
enhanced nephelometry. Serum albumin was measured
by the bromocresol purple method. A modiﬁed kinetic
Jaffe reaction was used to measure serum creatinine,
and the values from 1999 to 2000 were calibrated to the
Cleveland Clinic laboratory standard by multiplying by
1.013 and adding 0.147. Values from 2001 to 2004 did
not need correction. eGFR was calculated using the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation.16 CKD was deﬁned as an eGFR
of <60 ml/min/1.73 m2.
Body Composition Data
Missing and invalid DEXA data were accounted for
through multiple imputation by the National Center for
Health Statistics.17 Details of the DEXA quality control,
data validation, and multiple imputation procedures
are available elsewhere.17–20 DEXA data for at least 1
body region were imputed in 2472 participants
(21.3%). Muscle mass was quantiﬁed using the
appendicular skeletal muscle mass index (ASMI; total
lean mass of the 4 extremities divided by the square of
the height).21 Sarcopenia was deﬁned as ASMI of <5.45
kg/m2 in women and <7.26 kg/m2 in men.21,22 These
cutoffs correspond to 2 SDs below the sex-speciﬁc
means for healthy young adults 18 to 40 years of age
and are recommended by the consensus guidelines of
the European Working Group on Sarcopenia in Older
People.23,24 We examined ASMI rather total lean mass
based on this recommendation, and also because
appendicular lean mass is not confounded by changes
in visceral lean mass due to chronic disease and is likely
more relevant for functional status. Obesity was
determined as percentage of total body fat (TBF) greater
than 42.1% for women and 29.6% for men, corre-
sponding to the sex-speciﬁc 60th percentile for
the study sample22 and to the current World Health
Organization guidelines for BMI-deﬁned obesity.25,26
Outcome Variables
All-cause mortality was determined primarily through
probabilistic record matching with the National Death
Index and was available using public-use linkedKidney International Reports (2016) -, -–-
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ascertained through December 31, 2006,29 and then
additional data became available with mortality status
ascertained through December 31, 2011.30 The date and
cause of death for selected records were subjected to
data perturbation techniques because of concerns
regarding participant anonymity, but vital status was
not perturbed. The results of Cox proportional hazard
models are not affected by these data perturbation
techniques when compared with nonperturbed
restricted-use data.31,32
Statistical Analysis
Participant characteristics were examined within
body composition categories, for the overall cohort
and for those with eGFR of <60 ml/min/1.73 m2.
Differences across categories were tested for statistical
signiﬁcance using linear regression, logistic regres-
sion, or multinomial regression as appropriate.
KaplanMeier survivor functions were examined
within body composition categories for the overall
cohort and for those with eGFR of <60 ml/min/
1.73 m2 and tested for statistical signiﬁcance using the
Cox test of equality and accounting for NHANES
sampling weights. Cox proportional hazards models
were created to examine associations of body compo-
sition categories with all-cause mortality. We exam-
ined unadjusted models, followed by adjustment for
age, sex, and race/ethnicity, and then multivariable
models that included potential confounders of
the association of body composition with mortality,
including education level, physical activity,
smoking status, diagnosis of diabetes mellitus, hy-
pertension, cardiovascular disease, history of cancer
excluding nonmelanoma skin cancer, eGFR, and urine
albumincreatinine ratio. We then created separate
models additionally adjusting for serum albumin and
CRP, which, as markers of inﬂammation, may lie in
the causal pathway with body composition and mor-
tality. The functional form of continuous variables
was tested for linearity using higher-order terms and
categorical variables. We tested for interaction by
CKD status by including multiplicative interaction
terms in the models, and then repeated our analyses
separately among participants with eGFR of <60 ml/
min/1.73 m2 and $60 ml/min/1.73 m2. Effect modiﬁ-
cation by other covariates was tested using multipli-
cative interaction terms. The proportional hazards
assumption was tested by visual inspection of loglog
plots. All analyses used NHANES-appropriate
sampling weights and all except the KaplanMeier
analyses accounted for the complex multistage cluster
design using the “survey” command in Stata 13.1Kidney International Reports (2016) -, -–-(Stata Corporation, College Station, TX). A P value
of <0.05 was considered statistically signiﬁcant.
Sensitivity Analyses
We performed a matched-pair analysis in which we
repeated our analyses in a cohort in which each partici-
pant with an eGFR of<60 ml/min/1.73 m2 was uniquely
matched with a participant with eGFR of $60 ml/min/
1.73 m2 based on age (1 year), sex, and non-Hispanic
black status. To determine whether our ﬁndings were
explained by early mortality related to sarcopenia, we
repeated our analyses after excluding participants who
died within 24 months of their NHANES examination.
We explored confounding related to the use of
creatinine-based eGFR by repeating our analyses using
cystatin Cbased eGFR33 in the subgroup with cystatin
C measurements. To determine whether similar ﬁndings
were observed without using threshold deﬁnitions for
body composition components, we examined associa-
tions with all-cause mortality when ASMI and percent-
age of total body fat (%TBF) weremodeled as continuous
variables.
RESULTS
Participant Characteristics
Overall, 10.9% of participants were sarcopenic but
not obese, and 3.4% were sarcopenic-obese. Compared
with the other body composition categories,
sarcopenic-obese participants were older, more likely
to be male, and to be non-Hispanic white, current or
former smokers, less active, and to have hypertension,
cardiovascular disease, eGFR of <60 ml/min/1.73 m2,
and urine albumincreatinine ratio of >30 mg/g
(Table 1). They also had a higher prevalence of dia-
betes, lower serum albumin, and higher CRP than
nonsarcopenic nonobese and sarcopenic nonobese
participants but not compared with obese participants.
The mean BMI was similar between sarcopenic-obese
and nonsarcopenic nonobese participants, whereas for
the former group, %TBF was similar to that in obese
participants, and ASMI was similar to that in sarco-
penic non-obese participants.
Of 11,616 participants, 1101 had an eGFR of <60
ml/min/1.73 m2 (Table 2). Sarcopenia without obesity
and sarcopenic obesity were present in 12.5% and
9.7%, respectively. Differences in demographic charac-
teristics across categories were similar to those in the full
cohort, but there was less variation in the prevalence of
comorbidities. Patterns of variation across categories for
BMI, activity level, serum albumin, CRP, %TBF, and
ASMI were similar to those in the full cohort. Compared
with participants with eGFR of $60 ml/min/1.73 m2,
those with eGFR of <60 ml/min/1.73 m2 had an3
Table 1. Participant characteristics by body composition category in 11,616 participants of NHANES 1999–2004
Characteristic Nonsarcopenic, nonobese Sarcopenia only Obese only Sarcopenic-obese P
Proportion (%) 49.4 (0.9) 10.9 (0.4) 36.2 (0.7) 3.4 (0.2)
Age (yr) 42.2 (0.3) 47.9 (0.6) 49.5 (0.3) 63.4 (0.9) <0.001
Women (%) 50.3 (0.6) 52.6 (1.6) 51.6 (0.7) 42.3 (2.7) 0.009
Race/ethnicity (%) <0.001
Non-Hispanic white 69.9 (1.6) 76.5 (2.3) 73.7 (1.8) 81.7 (3.3)
Mexican American 7.2 (0.7) 7.0 (1.0) 7.5 (1.2) 4.9 (1.3)
Non-Hispanic black 12.1 (1.1) 3.7 (0.5) 10.2 (1.1) 1.9 (0.5)
Other 10.8 (1.3) 12.8 (1.8) 8.6 (1.3) 11.5 (2.7)
BMI (kg/m2) 25.8 (0.1) 20.9 (0.1) 33.7 (0.2) 25.2 (0.1) <0.001
BMI ‡ 30 kg/m2, proportion (%) 10.8 (0.5) 0 69.8 (1.2) 2.3 (0.6) <0.001
Education (% ‡ high school) 81.2 (0.8) 78.5 (1.5) 78.9 (0.8) 76.1 (3.0) 0.02
Smoking status <0.001
Never 51.1 43.3 50.8 40.9
Former 21.6 22.4 30.0 36.5
Current 27.4 34.2 19.2 22.5
Activity level (MET-min/wk, %) <0.001
0 13.1 (0.7) 19.7 (1.3) 19.6 (0.9) 25.0 (2.8)
<500 17.9 (1.3) 20.7 (1.5) 24.3 (0.8) 27.2 (2.4)
500--2000 35.1 (0.7) 36.0 (1.5) 35.2 (0.8) 30.4 (3.0)
>2000 33.8 (0.9) 23.6 (1.6) 20.9 (1.1) 17.5 (2.3)
Hypertension (%) 30.1 (1.0) 32.0 (2.0) 54.0 (1.1) 66.7 (3.4) <0.001
Diabetes mellitus (%) 5.5 (0.5) 4.5 (0.6) 14.2 (0.6) 10.9 (1.7) <0.001
Cardiovascular disease (%) 5.2 (0.5) 9.0 (0.8) 11.4 (0.6) 22.0 (2.7) <0.001
History of cancer (%) 4.7 (0.4) 8.8 (0.7) 7.4 (0.5) 17.5 (2.0) <0.001
eGFR <60 ml/min/1.73 m2 (%) 4.1 (0.3) 7.3 (0.8) 8.1 (0.4) 17.8 (1.9) <0.001
UACR >30 mg/g (%) 6.9 (0.4) 11.2 (1.2) 10.9 (0.7) 17.0 (2.0) <0.001
Serum bicarbonate (mEq/l) 24.2 (0.1) 24.6 (0.1) 23.9 (0.1) 24.6 (0.2) 0.001
Serum albumin (g/dl) 4.40 (0.01) 4.40 (0.01) 4.25 (0.01) 4.31 (0.02) <0.001
Serum CRP >1 mg/dl (%) 5.1 (0.4) 6.1 (0.7) 16.2 (0.7) 12.6 (1.8) <0.001
% Total body fat 30.2 (0.1) 29.1 (0.2) 40.4 (0.1) 38.4 (0.4) <0.001
ASMI (kg/m2) 7.6 (0.0) 5.6 (0.0) 8.4 (0.0) 6.0 (0.1) <0.001
Data are expressed as mean SE or as percentage (SE). ASMI, appendicular skeletal muscle mass index; BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular
ﬁltration rate; MET, metabolic equivalent; NHANES, National Health and Nutrition Examination Survey; UACR, urine albumincreatinine ratio.
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95% conﬁdence interval [CI] ¼ 1.36–1.85 after age,
sex, and race/ethnicity adjustment; HR ¼ 1.25, 95%
CI ¼ 1.06–1.48 after multivariable adjustment). There
was a nonlinear association of eGFR with mortality
(Table S1).
Associations of Sarcopenia Status With
Mortality
The median follow-up time for mortality status through
2006 and 2011 was 56 months (interquartile range
[IQR] ¼ 39–73) (707 deaths) and 113 months (IQR ¼
94–130) (1695 deaths), respectively. When classifying
body composition as either sarcopenic or nonsarcopenic,
sarcopenic participants had an increased risk of mor-
tality (Table 3, top panel) after multivariable adjustment
and after additional adjustment for CRP and serum al-
bumin. We found signiﬁcant effect modiﬁcation by CKD
status (P < 0.001 for interaction). After multivariable
adjustment, sarcopenia was associated with an increased
risk of mortality in participants with eGFR of $60 ml/
min/1.73 m2 (HR ¼ 1.34, 95% CI ¼ 1.15–1.57) but not
4those with eGFR of <60 ml/min/1.73 m2, although this
nearly reached statistically signiﬁcance (HR¼ 1.25, 95%
CI¼ 1.00–1.57). Adjustment for CRP and serum albumin
as markers of inﬂammation somewhat magniﬁed this risk
in participants with eGFR of $60 ml/min/1.73 m2 but
not <60 ml/min/1.73 m2. Analyses using the 2006
dataset yielded similar results (Table 3, bottom panel).
Associations of Body Composition Categories
With Mortality
Sarcopenic-obese participants had the highest overall
mortality (Figure 1a). After multivariable adjustment,
sarcopenia without obesity and sarcopenic obesity
were signiﬁcantly associated with increased mortality
compared with the nonsarcopenic nonobese phenotype
(Table 4, top panel). There was signiﬁcant effect
modiﬁcation of these associations by CKD status
(P ¼ 0.01). Among participants with eGFR of $60
ml/min/1.73 m2, both sarcopenia without obesity and
sarcopenic obesity were associated with an increased
risk of mortality after multivariable adjustment
(Table 4, top panel). The associations of all covariatesKidney International Reports (2016) -, -–-
Table 2. Participant characteristics by body composition category in 1101 participants of NHANES 1999–2004 with eGFR of <60 ml/min/1.73 m2
Characteristic Nonsarcopenic, nonobese Sarcopenia only Obese only Sarcopenic obese P
Proportion (%) 31.6 (1.8) 12.5 (1.2) 46.2 (2.1) 9.7 (1.1)
Age (yr) 70.6 (1.0) 75.2 (1.1) 70.8 (0.8) 77.2 (1.0) <0.001
Women (%) 69.0 (3.3) 53.3 (5.1) 61.3 (2.3) 35.5 (5.0) <0.001
Race/ethnicity (%) <0.001
Non-Hispanic white 79.5 (2.3) 88.5 (3.0) 82.4 (2.5) 90.3 (3.4)
Mexican American 1.6 (0.5) 1.6 (0.6) 1.5 (0.4) 2.0 (1.0)
Non-Hispanic black 11.7 (1.7) 2.1 (1.0) 8.6 (1.2) 0.6 (0.7)
Other 7.2 (2.2) 7.9 (2.7) 7.5 (2.3) 7.2 (3.0)
BMI (kg/m2) 26.2 (0.2) 21.7 (0.2) 32.8 (0.4) 25.5 (0.3) <0.001
BMI ‡ 30 kg/m2 proportion (%) 10.6 (2.3) 0 64.8 (2.2) 2.6 (2.0) <0.001
Education (% ‡ high school) 66.9 (3.1) 64.4 (6.0) 67.3 (2.5) 68.6 (5.7) 0.96
Smoking status 0.004
Never 61.0 40.1 51.3 45.2
Former 31.3 41.3 41.7 47.6
Current 7.7 18.6 7.0 7.2
Activity level (MET-min/wk, %) 0.03
0 25.1 (2.6) 39.1 (5.0) 34.4 (2.3) 33.9 (5.7)
<500 20.7 (2.6) 20.1 (4.3) 24.3 (2.6) 27.9 (5.7)
500--2000 33.8 (3.5) 25.6 (4.2) 26.8 (2.4) 29.5 (5.6)
>2000 20.4 (2.5) 15.2 (4.4) 14.5 (1.8) 8.7 (2.8)
Hypertension (%) 83.3 (2.7) 86.7 (4.1) 91.4 (1.4) 89.5 (3.8) 0.03
Diabetes mellitus (%) 20.8 (3.0) 17.5 (4.0) 26.6 (2.5) 18.1 (4.5) 0.19
Cardiovascular disease (%) 30.9 (3.2) 35.8 (4.3) 37.7 (2.7) 42.8 (5.7) 0.26
History of cancer (%) 17.8 (2.7) 19.9 (4.0) 17.7 (2.0) 30.9 (5.4) 0.11
UACR ‡30 mg/g (%) 26.1 (3.5) 31.9 (3.9) 28.5 (2.1) 32.1 (4.8) 0.63
Serum bicarbonate (mEq/l) 24.4 (0.2) 24.7 (0.3) 24.3 (0.2) 23.8 (0.4) 0.21
Serum albumin (g/dl) 4.27 (0.02) 4.15 (0.03) 4.14 (0.02) 4.17 (0.04) <0.001
Serum CRP ‡1 mg/dl (%) 7.5 (1.9) 10.6 (3.1) 17.3 (1.7) 12.6 (4.1) 0.007
% Total body fat 34.2 (0.4) 31.3 (0.6) 41.7 (0.4) 37.6 (0.6) <0.001
ASMI (kg/m2) 7.1 (0.1) 5.7 (0.1) 7.8 (0.1) 6.1 (0.1) <0.001
Data are expressed as mean SE or percentage (SE). ASMI, appendicular skeletal muscle mass index; CKD, chronic kidney disease; CRP, C-reactive protein; MET, metabolic equivalent;
NHANES, National Health and Nutrition Examination Survey; UACR, urine albumincreatinine ratio.
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presented in Table S1. Further adjustment for CRP and
serum albumin did not meaningfully change these
ﬁndings.
Among participants with eGFR of <60 ml/min/1.73
m2, sarcopenic nonobese and sarcopenic-obese partici-
pants had the highest overall mortality (Figure 1b).
Compared with nonsarcopenic nonobese participants,
no body composition category was associated with an
increased risk of death after multivariable adjustment
(Table 4, top panel). For obese and sarcopenic-obese
individuals, these associations differed signiﬁcantly
from participants without CKD (P value for interaction
by CKD status: sarcopenia without obesity, P ¼ 0.22;
obesity, P ¼ 0.01; sarcopenic obesity, P ¼ 0.003).
Furthermore, after accounting for inﬂammation, there
was a nonsigniﬁcant trend toward reduced risk of
death among obese participants (HR ¼ 0.77, 95%
CI ¼ 0.59–1.01). Findings were similar using the 2006
dataset, except that there was also a trend toward a
reduced risk of death among sarcopenic-obese partici-
pants, similar to obese persons, in those with eGFR
of <60 ml/min/1.73 m2 (Table 4, bottom panel).Kidney International Reports (2016) -, -–-Because obesity was the most populous body
composition category among participants with eGFR
of <60 ml/min/1.73 m2, and because prior studies have
suggested that obese dialysis patients may have the
greatest survival, we also examined associations with
mortality compared to that in obese persons (Figure 2a).
When obese participants were considered the reference
group, sarcopenia without obesity was signiﬁcantly
associated with increased mortality (HR ¼ 1.43, 95%
CI ¼ 1.05–1.95)). With shorter duration of follow-up in
the 2006 dataset, the risk of death was magniﬁed for
nonsarcopenic nonobese participants and for sarco-
penic nonobese participants, but not for sarcopenic-
obese persons (Figure 2b). Additional adjustment for
serum albumin and CRP increased the risk of death
relative to obesity for each of the other body compo-
sition categories.
There was signiﬁcant interaction between body
composition and race/ethnicity (P interaction ¼ 0.003
in the entire cohort); examination within the 2 eGFR
subgroups suggested that the mortality risk of sarco-
penia might be greater in non-Hispanic black partici-
pants compared to other race/ethnicity categories5
Table 3. Association of sarcopenia with all-cause mortality in 11,616 participants of NHANES 1999–2004*
Mortality status through 2011
Body composition
HR (95% CI)
Model 1 Model 2 Model 3 Model 4
Entire cohort (n ¼ 11,616)
Nonsarcopenic Reference Reference Reference Reference
Sarcopenic 2.52 (2.24--2.83) 1.43 (1.29--1.59) 1.28 (1.15--1.43) 1.32 (1.19--1.48)
Participants with eGFR $60 ml/min/1.73 m2 (n ¼ 10,515)
Nonsarcopenic Reference Reference Reference Reference
Sarcopenic 2.48 (2.11--2.92) 1.54 (1.34--1.78) 1.34 (1.15--1.57) 1.42 (1.21--1.66)
Participants with eGFR <60 ml/min/1.73 m2 (n ¼ 1101)
Nonsarcopenic Reference Reference Reference Reference
Sarcopenic 1.89 (1.54--2.32) 1.33 (1.05--1.68) 1.25 (1.00–1.57) 1.24 (0.98–1.58)
Mortality status through 2006
Body composition
HR (95% CI)
Model 1 Model 2 Model 3 Model 4
Entire cohort (n ¼ 11,616)
Nonsarcopenic Reference Reference Reference Reference
Sarcopenic 2.83 (2.37--3.38) 1.51 (1.22--1.86) 1.33 (1.06--1.67) 1.38 (1.11--1.73)
Participants with eGFR $60 ml/min/1.73 m2 (n ¼ 10,515)
Nonsarcopenic Reference Reference Reference Reference
Sarcopenic 2.89 (2.27--3.68) 1.74 (1.35--2.25) 1.47 (1.12--1.94) 1.56 (1.19--2.04)
Participants with eGFR <60 ml/min/1.73 m2 (n ¼ 1101)
Nonsarcopenic Reference Reference Reference Reference
Sarcopenic 1.85 (1.36--2.52) 1.21 (0.83–1.78) 1.17 (0.84–1.68) 1.19 (0.84–1.68)
Model 1: unadjusted. Model 2: adjusted for age, sex, race/ethnicity. Model 3: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes
mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, and log-transformed urine albumin-creatinine ratio. Model 4:
adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than
nonmelanoma skin cancer), eGFR categories, log-transformed urine albumincreatinine ratio, serum albumin, log-transformed C-reactive protein. CI, conﬁdence interval; CKD, chronic
kidney disease; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; NHANES, National Health and Nutrition Examination Survey.
*P value for interaction by CKD status: mortality status through 2011, P < 0.001; mortality status through 2006, P ¼ 0.002. Boldface values indicate P < 0.05.
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on eGFR.
Sensitivity Analyses
As the differences that we observed between the 2
eGFR subgroups could have been related to underlying
differences in demographic characteristics, we repeated
our analyses in a cohort in which each participant with
an eGFR of <60 ml/min/1.73 m2 was uniquely matched
with a participant with eGFR of $60 ml/min/1.73 m2
based on age (1 year), sex, and non-Hispanic black
status. This resulted in 965 unique pairs (957/965 with
age difference ¼ 0 years). These results did not differ
substantively from our main results, and there was a
signiﬁcant interaction by CKD status (P ¼ 0.04)
(Table S3). After excluding participants who died in
the ﬁrst 2 years of follow-up, sarcopenia was signiﬁ-
cantly associated with mortality in participants with
and without eGFR of <60 ml/min/1.73 m2 (Table S4).
Compared with obese participants with eGFR of <60
ml/min/1.73 m2, the mortality HRs for those who were
sarcopenic nonobese or sarcopenic-obese increased in
magnitude (Table S5). Cystatin C data were available in
3949 participants, 755 of whom had an eGFR of <60
ml/min/1.73 m2. Repeating our analyses using cystatin6C eGFR in this smaller sample yielded qualitatively
similar results (Tables S6 and S7). Modeling ASMI and
%TBF as continuous variables demonstrated an asso-
ciation of higher %TBF with lower risk of mortality
only among participants with CKD (Table S8). There
was a similar nonsigniﬁcant association when restricted
to sarcopenic individuals.
DISCUSSION
In a nationally representative cohort, we found that the
risk of death in persons with CKD differs if muscle and fat
mass are examined together rather than in isolation. BMI
is of limited utility in this regard. Nearly 10% of par-
ticipants with CKD and reduced eGFR were sarcopenic-
obese, and their mean BMI was no different than that
of individuals with normal body composition.
We hypothesized that associations of sarcopenia
and sarcopenic obesity with increased mortality
would be greater in persons with CKD than in those
without. Our ﬁndings do not support this hypothesis.
Although sarcopenia in the absence of obesity was an
independent risk factor for increased mortality, this
relationship was modiﬁed by eGFR. Among partici-
pants with CKD, the increased risk of death was pre-
sent only when compared with that of obese personsKidney International Reports (2016) -, -–-
PP
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Figure 1. KaplanMeier survival curves for all-cause mortality
by body composition category in participants of the National
Health and Nutrition Examination Survey (NHANES) 1999–2004.
(a) KaplanMeier survival curves by body composition category in
11,616 participants. (b) KaplanMeier survival curves by body
composition category in 1101 participants with eGFR of <60 ml/min/
1.73 m2. P values calculated using the Cox test of equality and ac-
counting for NHANES sampling weights.
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contrary to our hypothesis, sarcopenic obesity was not
associated with higher mortality among persons with
CKD, in contrast to those with eGFR of $60 ml/min/
1.73 m2; rather, in our initial analyses of mortality
status ascertained through 2006, the results suggested a
reduced risk of death in these participants similar to
that seen among obese individuals. Although this
protective association seemed to be attenuated with
greater duration of follow-up time (when mortality
status was ascertained through 2011), the risk of death
was still not signiﬁcantly increased.
Whereas the association of body composition
abnormalities with outcomes has been studied exten-
sively in the ESRD population, it has been less well-
examined in persons with predialysis CKD. MostKidney International Reports (2016) -, -–-studies have focused on obesity, using BMI as the
deﬁning metric.8,34,35 Muscle mass has been examined
directly and indirectly in only a few studies, with
conﬂicting results. One report of 287 CKD patients
found increased mortality among those who were sar-
copenic,4 whereas another using NHANES data found
no association of total lean body mass with survival in
persons with CKD.6 Conversely, 2 studies reported that
lower urinary creatinine excretion was associated with
an increased risk of death in CKD patients, suggesting
that lower muscle mass is a poor prognostic factor.5,7
However, it is not clear that these associations were
due to differences in muscle mass. In the Chronic Renal
Insufﬁciency Cohort study, fat-free mass measured by
bioelectrical impedance analysis was only moderately
correlated with creatinine excretion and did not simi-
larly associate with mortality.7 Factors other than
muscle mass, such as dietary intake and the ability to
complete a 24-hour urine collection, may have medi-
ated differences in measured urinary creatinine excre-
tion in these studies.
Appendicular skeletal muscle mass may be more
appropriate to examine in relation to mortality, as it is
more directly related to functional ability and is not
confounded by differences in visceral lean mass. Our
report used a threshold for low appendicular muscle
mass that is recommended by the European consensus
guidelines for deﬁning sarcopenia.23 Although the
current guidelines also recommend including func-
tional measures in the deﬁnition, we focused on
muscle mass because of the limited number of in-
dividuals with functional assessments in this
NHANES cohort. Despite this limitation, our ﬁndings
demonstrate that low muscle mass is predictive of
mortality risk in the general population and in per-
sons with CKD.
There are several possible explanations for the
association of sarcopenia with mortality in persons
with CKD. Kidney disease may cause muscle wasting
via accelerated muscle protein breakdown, possibly
mediated by inﬂammation or insulin resistance.36–38
This could affect survival through several mecha-
nisms. Better preserved muscle mass could help main-
tain functional status, decreasing the risk of falls,
fractures, and the negative effects of a sedentary life-
style.23 Greater skeletal muscle mass could improve
metabolism, enhance peripheral glucose disposal, and
increase energy stores.39 Intriguingly, inhibition of
muscle proteolysis in a murine model of CKD not only
preserved muscle mass but improved survival as
well.40 If the quantity of functional skeletal muscle
indeed mediates mortality risk in CKD, this could also
explain some of the early survival beneﬁt attributed to
obesity. Even in the CKD subgroup, the individuals in7
Table 4. Association of body composition categories with all-cause mortality in 11,616 participants of NHANES 1999–2004*
Mortality status through 2011
Body composition
HR (95% CI)
Model 1 Model 2 Model 3 Model 4
Entire cohort (n ¼ 11,616)
Nonsarcopenic nonobese Reference Reference Reference Reference
Sarcopenic 2.72 (2.25--3.29) 1.62 (1.33--1.99) 1.35 (1.10--1.67) 1.32 (1.06--1.66)
Obese 2.09 (1.74--2.50) 1.27 (1.05--1.52) 1.09 (0.90–1.32) 0.98 (0.81–1.18)
Sarcopenic-obese 6.99 (5.65--8.65) 1.69 (1.38--2.06) 1.35 (1.09--1.66) 1.28 (1.04--1.57)
Participants with eGFR $60 ml/min/1.73 m2 (n ¼ 10,515)
Nonsarcopenic nonobese Reference Reference Reference Reference
Sarcopenic 2.80 (2.14--3.66) 1.79 (1.37--2.35) 1.44 (1.07--1.93) 1.45 (1.07--1.97)
Obese 2.24 (1.78--2.81) 1.41 (1.12--1.77) 1.21 (0.96–1.54) 1.09 (0.87–1.37)
Sarcopenic-obese 7.45 (5.65--9.82) 2.09 (1.61--2.70) 1.64 (1.26--2.13) 1.57 (1.19--2.05)
Participants with eGFR <60 ml/min/1.73 m2 (n ¼ 1101)
Nonsarcopenic nonobese Reference Reference Reference Reference
Sarcopenic 1.79 (1.32--2.44) 1.46 (1.06--2.02) 1.24 (0.89–1.71) 1.14 (0.80–1.64)
Obese 0.93 (0.72–1.19) 1.00 (0.77–1.30) 0.87 (0.67–1.12) 0.77 (0.59–1.01)
Sarcopenic-obese 1.83 (1.34--2.48) 1.19 (0.88–1.62) 1.05 (0.75–1.46) 0.97 (0.70–1.35)
Mortality status through 2006
Body composition
HR (95% CI)
Model 1 Model 2 Model 3 Model 4
Entire cohort (n ¼ 11,616)
Nonsarcopenic nonobese Reference Reference Reference Reference
Sarcopenic 2.99 (2.34--3.83) 1.68 (1.29--2.19) 1.39 (1.03--1.87) 1.34 (1.00–1.83)
Obese 1.93 (1.51--2.47) 1.18 (0.92–1.50) 1.00 (0.77–1.28) 0.86 (0.67–1.12)
Sarcopenic-obese 7.14 (5.43--9.40) 1.65 (1.18--2.30) 1.23 (0.83–1.84) 1.17 (0.81–1.70)
Participants with eGFR $60 ml/min/1.73 m2 (n ¼ 10,515)
Nonsarcopenic nonobese Reference Reference Reference Reference
Sarcopenic 3.13 (2.20--4.48) 1.95 (1.38--2.75) 1.52 (1.02--2.26) 1.51 (1.00–2.30)
Obese 2.11 (1.53--2.90) 1.34 (0.97–1.85) 1.15 (0.83–1.60) 1.00 (0.71–1.40)
Sarcopenic-obese 8.26 (5.51--12.38) 2.30 (1.42--3.72) 1.75 (1.07--2.87) 1.63 (1.02--2.61)
Participants with eGFR <60 ml/min/1.73 m2 (n ¼ 1101)
Nonobese nonsarcopenic Reference Reference Reference Reference
Sarcopenic 1.79 (1.17--2.74) 1.38 (0.87–2.18) 1.24 (0.80–1.90) 1.16 (0.74–1.81)
Obese 0.87 (0.62–1.24) 0.94 (0.68–1.29) 0.77 (0.55–1.07) 0.67 (0.47--0.95)
Sarcopenic-obese 1.61 (1.03--2.50) 0.95 (0.57–1.58) 0.77 (0.48–1.23) 0.73 (0.46–1.17)
Model 1: unadjusted. Model 2: adjusted for age, sex, race/ethnicity. Model 3: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes
mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, and log-transformed urine albumin-creatinine ratio. Model 4:
adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than
nonmelanoma skin cancer), eGFR categories, log-transformed urine albumincreatinine ratio, serum albumin, log-transformed C-reactive protein. CI, conﬁdence interval; CKD, chronic
kidney disease; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; NHANES, National Health and Nutrition Examination Survey.
*P value for interaction by CKD status: mortality through 2011, P ¼ 0.01; mortality status through 2006, P ¼ 0.01. Boldface values indicate P < 0.05.
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those with normal body composition.
Accelerated aging likely also contributes to the
development of sarcopenia in persons with CKD.
Adjustment for reduced activity level and comorbid
conditions, markers of unsuccessful aging, attenuated
the association with mortality but did not fully
explain our ﬁndings. Similarly, inﬂammation has
been linked with the development of sarcopenia41,42;
however, our results remained signiﬁcant even after
adjustment for serum albumin and CRP. Sarcopenia
may be a marker of accelerated aging independent of
these factors.43 On the other hand, although we
attempted to account for differences in comorbidity
and other characteristics among body composition8categories, residual confounding may still explain
some of our ﬁndings. In addition, sarcopenia could
simply be a marker for sicker individuals with a
greater burden of chronic illness. If this were the case,
then our results could be due to an excess of early
deaths among these sicker individuals. However, we
did not see attenuation of risk with longer follow-up
or when we excluded early mortality. It is possible
that exclusion of death beyond the ﬁrst 2 years might
be required to detect such an effect. Regardless, we
cannot exclude the possibility that differences in
body composition are simply markers for other
health-related characteristics.
Our ﬁndings illustrate the complexity of studying
body composition in patients with CKD, even beforeKidney International Reports (2016) -, -–-
00.5
1
1.5
2
2.5
3
Age, sex, race adjusted MulƟvariable adjusted InflammaƟon adjusted
HR
 (9
5%
 C
I)
0
0.5
1
1.5
2
2.5
3
Age, sex, race adjusted MulƟvariable adjusted InflammaƟon adjusted
HR
 (9
5%
 C
I)
Non-sarcopenic non-obese Sarcopenic Obese Sarcopenic-obese
Non-sarcopenic non-obese Sarcopenic Obese Sarcopenic-obese
a
b
* *
**
*
*
Figure 2. All-cause mortality compared to that in obese persons
among National Health and Nutrition Examination Survey (NHANES)
participants with an estimated glomerular ﬁltration rate (eGFR)
of <60 ml/min/1.73 m2. CI, confidence interval; HR, hazard ratio. (a)
Mortality ascertained through 2011. (b) Mortality ascertained
through 2006. Multivariable-adjusted model adjusted for age, sex,
race/ethnicity, education level, activity level, smoking status, diag-
nosis of diabetes mellitus, hypertension, cardiovascular disease,
history of cancer (other than nonmelanoma skin cancer), eGFR
categories, and log-transformed urine albumincreatinine ratio.
Inflammation-adjusted model additionally adjusted for serum albu-
min and log-transformed C-reactive protein. CI, confidence interval;
HR, hazard ratio.
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of $60 ml/min/1.73 m2, sarcopenia was associated with
mortality whether we classiﬁed participants based on
sarcopenia status alone or simultaneously accounted for
adiposity. When classifying participants with reduced
eGFR based on sarcopenia status alone, it appeared
there was a weaker association with mortality than in
participants without CKD. A more detailed classiﬁca-
tion of body composition was required to clarify this
association. In individuals with reduced eGFR, whether
sarcopenia was associated with an increased risk of
death depended on whether an individual was also
obese by %TBF criteria. The favorable prognostic
value of obesity seemed to outweigh the mortality risk
of sarcopenia, although this effect diminished with
longer follow-up time. Surprisingly, excluding early
mortality in our sensitivity analyses magniﬁed the risk
of death in persons with CKD. This is in stark contrast
to the general population cohort with eGFR of $60
ml/min/1.73 m2.Kidney International Reports (2016) -, -–-Most interventional studies in the general popula-
tion have targeted either obesity or sarcopenia, but
few have examined the sarcopenic-obese phenotype
directly.44 Concerns have been raised about weight
loss interventions in these individuals, because mus-
cle mass is lost along with fat mass. It has been sug-
gested that exercise should accompany supervised
weight loss protocols in these circumstances.44 We are
not aware of any interventional studies addressing
this issue in CKD patients, and our data do not indi-
cate whether interventions targeted at sarcopenic-
obese CKD patients could be expected to improve
survival. Although some would argue that weight loss
may not be appropriate given the reduced risk of
death with obesity and sarcopenic obesity in early
follow-up, exercise including strength training seems
a logical intervention to test. This could be expected
to affect outcomes such as disability, falls, and quality
of life, which may be adversely affected by both
sarcopenia and obesity.45,46
Several limitations of our study should be noted.
The number of participants with eGFR of <60 ml/min/
1.73 m2 was relatively small, thus limiting the power to
detect signiﬁcant associations. For example, in the CKD
cohort, the association of sarcopenia with mortality
might have been statistically signiﬁcant had a larger
sample size been available for analysis. Similarly, when
we further characterized body composition, the small
sample of sarcopenic-obese individuals with CKD
limited our ability to detect statistically signiﬁcant
associations. Nevertheless, there was signiﬁcant effect
modiﬁcation by CKD status even within the smaller
matched-pairs cohort, and the direction and magnitude
of the point estimates were similar to our main results.
Also, the deﬁnition of obesity did not account for the
distribution of adipose tissue, and others have used
different cutpoints for deﬁning obesity based on
adiposity. However, sarcopenic obesity deﬁned using
this %TBF cutoff has been associated with disability in
community-dwelling elderly,22 and our previous work
found that American Society of Bariatric Physicians
cutpoints (30% for women and 25% for men) would
provide limited discriminatory power because they
would classify >90% of individuals with CKD stage 3
and 4 as obese.10 Future studies should examine the
interaction of abdominal obesity with sarcopenia in the
CKD population. DEXA may overestimate lean mass in
persons with edema; this could have attenuated our
risk estimates, as participants with CKD would be most
likely to have edema and to have an overestimation of
lean mass. As only cross-sectional laboratory data were
available, we could not deﬁne CKD based on the
presence of an eGFR of <60 ml/min/1.73 m2 for at least
3 months. Finally, given the observational nature of9
CLINICAL RESEARCH L Androga et al.: Sarcopenia, Obesity, and Mortalitythis study, we have determined associations but cannot
comment on causality.
In conclusion, sarcopenia is associated with
increased mortality in the CKD population, but the
presence of obesity modiﬁes this relationship. Unlike in
the general population, obesity seems to blunt the
mortality risk of sarcopenia in persons with CKD.
Future studies should assign supervised weight loss
and different types of exercise interventions after ac-
counting for the complex alterations in body compo-
sition that occur in CKD patients but are not detected
by BMI.
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